As of 1 December, DTU has appointed Professor Thomas Lars Andresen as new head of department at
DTU Nanotech. For a period, he has been acting head of the department, where he was previously deputy head.
“Thomas Andresen has a high level of academic competency and in his time at DTU, he has demonstrated considerable skill at building up new research areas,” says DTU President Anders Bjarklev about the appointment, and continues: “He has high ambitions for the department’s academic area, and he also has extensive leadership experience—partly from building up one of the department’s biggest academic groups, and partly from his time as deputy head. Thomas is international in his outlook, strong on innovation, and knows the department well. I have high expectations in terms of where he will take the department in future.”
Throughout his career, Thomas Andresen has received several awards for his research, including a prestigious Sapere Aude DFF-Advanced Grant in 2015 from the Danish Council for Independent Research.
“DTU Nanotech’s employees are unusually committed, and bearers of a culture which is deeply rooted in dedication and professionalism. I am very much looking forward to developing this culture further, and to working with our strategy within research and teaching,” says Thomas Andresen, who describes the department’s successes within research and innovation as ‘unique’.
"Thomas is international in his outlook, strong on innovation, and knows the department well."
President Anders O. Bjarklev
“With the right strategy and organization for the future, I believe we can reach new heights within a number of research areas, including advanced materials research. We have the ideas and the right researchers, and we must carry out research for the benefit of society by creating new technologies and new enterprises.”
Thomas Andresen’s expertise lies within drug delivery, in other words systems for bringing immunostimulatory molecules up to the cancer patient’s own immune cells and programming them to recognize cancer cells.
The new head of department was born in 1972, and after completing his MSc in Chemical Engineering at DTU and doing a PhD at the University of Auckland, he was employed as head of a research department at LiPlasome Pharma in Hørsholm, where he was appointed director of R&D.
In 2007, he was employed as a senior researcher at the then Risø National Laboratory, and the following year moved to DTU Nanotech as a senior researcher. In 2012 he was made a full professor. He is also cofounder of two companies, Nanovi and Torque Therapeutics.
DTU spin-out launching a new technology for cancer treatment
Start-up company Nanovi has just had a biodegradable tumour marker approved, which can provide a more precise radiation therapy for patients with lung and oesophageal tumours. Read the article...
Nanoparticles boost the immune system in cancer patients
A new type of cancer immunotherapy is being developed at DTU Nanotech and realised in the spin-out company, MonTa Biosciences. Nanoparticles that stimulate the immune system are developed with the aim to cure patients with metastatic cancer. Read the article...
Danish Council for Independent Research awards DKK 34.6 million
Four DTU researchers have been awarded the Danish Council for Independent Research’s Sapere Aude grants. The grants amount to DKK 34.6 million for research within such wide-ranging fields as a quantum internet, cancer treatment, dissemination of information in social networks, and IT security. Read the article...
Cancer treatment is all about precision
Cancer patients can look forward to much more effective radiation treatment involving a new technology: a nano-scale marker that establishes the position of tumours in the body with pinpoint accuracy. Read the article...